Orchestra BioMed Holdings, Inc. (OBIO)

In the past six months, Orchestra BioMed Holdings, Inc.'s stock price has been impacted by several events. The stock price experienced a gain of 5.39% on February 6, 2026. Darren Sherman, Director and President/COO, reported the vesting of a performance-based stock option for 34,974 shares on January 28, 2026. Orchestra BioMed was set to receive up to $21 million in proceeds from the acquisition of Vivasure by Haemonetics, announced on January 12, 2026. Barclays issued a price target of $12.00 for OBIO on January 9, 2026. TD Cowen initiated coverage of Orchestra BioMed Holdings with a "buy" recommendation on December 11, 2025. The company announced presentations on its AVIM Therapy and Virtue SAB programs at the ICI Meeting on December 8, 2025. The company reported its quarterly earnings on November 10, 2025, missing analysts' consensus estimates. Piper Sandler reiterated an "Overweight" rating and a $15.00 price target for Orchestra BioMed on September 11, 2025. Insider sentiment has been positive over the last year, with 12 different insiders making purchases. Short interest in the stock recently increased by 6.80%, suggesting a decrease in investor sentiment.

Information regarding the demand seasonality for Orchestra BioMed Holdings, Inc.'s products and services is not readily available in the provided search results.

Orchestra BioMed Holdings, Inc. (OBIO) is a biomedical innovation company focused on accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies, operating within the Healthcare sector. Its flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for hypertension and Virtue Sirolimus AngioInfusion Balloon (SAB) for atherosclerotic artery disease. The company's pipeline also includes Atrioventricular Interval Modulation (AVIM) for lowering blood pressure and Cardiac Neuromodulation Therapy for heart failure (CNT-HF). Additionally, Orchestra BioMed offers FreeHold devices, other minimally invasive surgery enabling devices, and the Pure-Vu system. Orchestra BioMed has strategic collaborations with Medtronic, Inc. for AVIM therapy and with Terumo Corporation for the development and commercialization of Virtue SAB.

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States and is headquartered in New Hope, Pennsylvania. The company conducts early- and mid-stage clinical studies in North America. Through its strategic collaborations with global leaders like Medtronic and Terumo Corporation, the company aims for global commercialization of its products.

In the past year, Orchestra BioMed has generally maintained a "Moderate Buy" consensus rating from analysts, with an average rating score of 2.71 based on various buy, hold, and sell ratings. Insider sentiment has been positive, with significant open-market purchases by insiders. Events such as receiving proceeds from an acquisition and positive analyst coverage from firms like TD Cowen and Barclays have likely contributed positively to its reputation.

The ownership structure of Orchestra BioMed Holdings (OBIO) stock is a mix of institutional, retail, and individual investors. Approximately 6.91% of the company's stock is owned by Institutional Investors, 28.84% by Insiders, and 64.26% by Public Companies and Individual Investors. Major institutional shareholders include Rtw Investments, Lp, Perceptive Advisors Llc, Vanguard Group Inc, Alyeska Investment Group, L.P., Pathstone Holdings, LLC, Affinity Asset Advisors, LLC, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, BlackRock, Inc., Knoll Capital Management, LLC, and Price T Rowe Associates Inc /md/.